表紙
市場調査レポート

PharmaPoint:潰瘍性大腸炎(UC) - 世界の医薬品の予測と市場分析

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

発行 GlobalData 商品コード 299707
出版日 ページ情報 英文 341 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
PharmaPoint:潰瘍性大腸炎(UC) - 世界の医薬品の予測と市場分析 PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
出版日: 2014年09月30日 ページ情報: 英文 341 Pages
概要

世界の主要10ヶ国の潰瘍性大腸炎(UC)治療薬市場は、2012年には42億米ドルに達し、2022年には約68億米ドルにまで拡大する(その間の年平均成長率(CAGR)は4.9%)、と予測されています。大手製薬企業からの新規治療薬(Johnson & JohnsonのSimponiや武田薬品工業のEntyvioなど)の上市が市場成長を促進する一方、特許失効に伴うバイオシミラーの発売などが今後の市場成長の妨げとなる可能性があります。

当レポートでは、全世界の潰瘍性大腸炎(UC)の市場の現状と将来展望について分析し、疾患の概要や今後の疫学的予測、主要国での予防体性、主要企業のプロファイルと代表的製品、市場のアンメットニーズと将来的な機会、現在治験中のパイプライン製品の情報、今後の市場規模と影響要因などを調査して、その結果をお届けします。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態
    • 病因
    • 病態
  • 症状
    • 生活の質(QoL)

第4章 疫学

  • 疾患の背景
  • リスク要因と共存症
    • 白人・ユダヤ人の感染リスクは37倍高い
    • 第一度近親者の家族歴:発症リスクは3倍高くなる
    • 喫煙者の発症リスクは、禁煙者・非喫煙者よりも低い
  • 世界各国での傾向
    • 米国
    • 欧州主要5ヶ国
    • 日本
    • カナダ
    • 中国
    • インド
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法
  • 潰瘍性大腸炎(UC)の疫学的予測(今後11年間分)
    • 潰瘍性大腸炎の発症率
    • 年齢別の発症率
    • 男女別の発症率
    • 年齢調整済みの発症率
  • 潰瘍性大腸炎の有病者数の予測(今後11年間分)
    • 潰瘍性大腸炎の有病者数
    • 有病者数(年齢別)
    • 有病者数(男女別)
    • 年齢調整済みの有病者数
  • 議論
    • 疫学的予測に関する考察
    • 分析の限界
    • 分析の強み

第5章 疾患の管理

  • 診断・治療の概要
    • 診断
    • 治療のガイドラインと代表的な処方薬
    • 臨床診療
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • カナダ
  • 中国
  • インド

第6章 競合企業の評価

  • 概要
  • 競合企業の戦略的評価
  • 製品プロファイル:主要ブランド
    • Remicade (infliximab)
    • Humira (adalimumab)
    • Simponi (golimumab)
    • Entyvio (vedolizumab)
    • Apriso (mesalamine)
    • Asacol HD (mesalamine)
    • Lialda (mesalamine)
    • Pentasa (mesalamine)
    • Colazal (balsazide disodium)
    • Giazo (balsalazide disodium)
    • sfRowasa (mesalamine)
    • Uceris (budesonide)
    • その他の薬剤クラス
  • バイオシミラー
    • 序論
    • 主な自己免疫疾患に対する効力:Inflectra (Hospira) vs. Remicade (J&J)
    • 免疫学コミュニティにおけるバイオシミラー
    • 開発中のバイオシミラー
    • 製薬業界全体に対するバイオシミラーの影響力
    • バイオシミラー市場の予測

第7章 市場機会とアンメットニーズ

  • 概要
  • アンメットニーズ
    • 重篤な患者の根治療法
    • 重症度別の診断マーカー
    • 個別化医療
    • ステロイドの代替薬
    • 新たな経口薬
    • 関連疾患(大腸癌)リスクの引き下げのための予防薬
    • 感染症の有害事象の管理改善
  • アンメットニーズのギャップの分析
  • 重症度と大腸癌バイオマーカー・ベースの予測ツール
  • 難治性疾患の前兆

第8章 パイプライン評価

  • 概要
  • 治験マッピング
    • 国別の治験マッピング
  • 相別・治験段階別の治験進行状況
  • 治験中の有望な医薬品
    • Entyvio (vedolizumab)
    • Xeljanz (tofacitinib)
    • Kappaproct (DIMS 0150)

第9章 現在・将来の市場参入企業

  • 概要
  • 企業戦略の傾向
  • 企業プロファイル
    • Johnson & Johnson
    • AbbVie
    • 武田薬品工業
    • Roche
    • Warner Chilcott
    • Salix Pharmaceuticals/Santarus
    • Shire Pharmaceuticals
    • Ferring Pharmaceuticals
    • Pfizer
    • InDeX Pharmaceuticals

第10章 市場の見通し

  • 世界市場
    • 市場予測
    • 促進・阻害要因:世界的課題
  • 米国市場
    • 市場予測
    • 近年の主な動向
    • 市場促進・阻害要因
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • カナダ
  • 中国
  • インド

第11章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC005EPIDR

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Simponi and Entyvio, which will favor the increased uptake of biologics in the US, 5EU, Japan, and Canada. Although the number of UC prevalent cases is plateauing in the West, globally, the number of cases is rising, a phenomenon that will contribute to market growth over the next decade. Another event affecting the market is the launch of biosimilars, given the patent expiry of the UC blockbusters, Remicade and Humira, in the US in 2018 and 2016, respectively. However, the lack of an established regulatory path for biosimilars in the US presages the slow uptake of these products in this market, which could limit their availability, and consequently, inhibit the growth of the UC market.

Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

Overall, major barriers to the growth of the UC market include -

  • Remicade and Humira losing patent protection in the mid-forecast
  • Austerity measures favoring generic prescribing
  • Biosimilars are predicted to face low uptake due to the lack of regulatory guidelines in some markets, such as the US

Highlights

Key Questions Answered

  • How will the UC market (sales and patient numbers) evolve over the 10-year forecast period from 2012 to 2022?
  • How will the launch of the first-in-class Entyvio change the landscape of the UC market?
  • Which brands and specific drug classes did physicians select for their UC patients in 2012 and how do they foresee their prescribing behavior evolving over the next five years?
  • How will the launch of late-stage pipeline therapies such as etrolizumab and Kappaproct shape the future treatment landscape?
  • What are the remaining unmet needs and opportunities for drug developers within the UC market?

Key Findings

  • The UC market has predominantly been driven by two TNF blockers, namely J&J's Remicade and AbbVie's Humira. Although these TNF blockers have monopolized the UC market for almost a decade, the balance is about to be tipped, with Takeda's Entyvio and J&J's Simponi launch in 2014, stealing market share from Humira and Remicade.
  • Remicade and Humira will also be hit by their respective loss of patent protection in 2018 (US), 2015 (EU) and 2016 (US), 2018 (EU). Europe has already approved a biosimilar to Remicade, Celltrion's Remsima, which will be marketed by Hospira under the brand name Inflectra in the EU. Due to lack of regulatory guidelines and the current debate about indication extrapolation for biosimilars based on a clinical trial in one indication, initial biosimilar uptake will be low, but by the end of the forecast period, in 2022 infliximab, adalimumab and golimumab biosimilars are forecast to become an established part of the UC market.
  • During the coming decade, Europe is expecting the approval and launch of a UC colectomy rescue therapy, InDex Pharmaceuticals' Kappaproct. Kappaproct is targeting a small patient population group, but due to the involvement of key gastroenterologists in the development of this therapy, it will likely be welcomed for use in this new treatment setting, which has never been addressed before by a pharmaceutical product. In addition, Pfizer's Xeljanz is expected to face low uptake post its estimated launch in 2017, owing to the controversy surrounding its rejection by the EMA for its primary indication, rheumatoid arthritis.

Scope

  • Overview of UC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
  • Annualized UC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2022.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the UC therapeutics markets.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late stage pipeline drugs.
  • Analysis of the current and future market competition in the global UC therapeutics markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global UC therapeutics markets.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global UC therapeutics markets in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global UC therapeutics markets from 2012-2022.
  • Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
    • 3.2.1. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
    • 4.2.1. Being Caucasian and Jewish can increase the risk of UC by almost 37 times
    • 4.2.2. A family history of UC in first-degree relatives can increase the risk of the disease by almost three-fold
    • 4.2.3. Current smokers have a lower risk of developing UC than former smokers or never smokers
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan
    • 4.3.4. Canada
    • 4.3.5. China
    • 4.3.6. India
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast of UC (2012-2022)
    • 4.5.1. Incident Cases of UC
    • 4.5.2. Age-Specific Incident Cases of UC
    • 4.5.3. Sex-Specific Incident Cases of UC
    • 4.5.4. Age-Standardized Incidence Rates
  • 4.6. Epidemiological Forecast for UC Prevalent Cases (2012-2022)
    • 4.6.1. Prevalent Cases of UC
    • 4.6.2. Age-Specific Prevalent Cases of UC
    • 4.6.3. Sex-Specific Prevalent Cases of UC
    • 4.6.4. Age-Standardized Prevalence Rate of UC in All Markets
  • 4.7. Discussion
    • 4.7.1. Epidemiological Forecast Insight
    • 4.7.2. Limitations of the Analysis
    • 4.7.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 5.1.3. Clinical Practice
  • 5.2. US
  • 5.3. France
  • 5.4. Germany
  • 5.5. Italy
  • 5.6. Spain
  • 5.7. UK
  • 5.8. Japan
  • 5.9. Canada
  • 5.10. China
  • 5.11. India

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Strategic Competitor Assessment
  • 6.3. Product Profiles - Major Brands
    • 6.3.1. Remicade (infliximab)
    • 6.3.2. Humira (adalimumab)
    • 6.3.3. Simponi (golimumab)
    • 6.3.4. Entyvio (vedolizumab)
    • 6.3.5. Apriso (mesalamine)
    • 6.3.6. Asacol HD (mesalamine)
    • 6.3.7. Lialda (mesalamine)
    • 6.3.8. Pentasa (mesalamine)
    • 6.3.9. Colazal (balsazide disodium)
    • 6.3.10. Giazo (balsalazide disodium)
    • 6.3.11. sfRowasa (mesalamine)
    • 6.3.12. Uceris (budesonide)
    • 6.3.13. Other Drug Classes Used in the Treatment of UC
  • 6.4. Biosimilars
    • 6.4.1. Introduction
    • 6.4.2. Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases
    • 6.4.3. Biosimilars in the Immunology Community
    • 6.4.4. By the Numbers: Biosimilars in Development
    • 6.4.5. The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry
    • 6.4.6. Biosimilars' Forecast

7. Opportunity and Unmet Need

  • 7.1. Overview
  • 7.2. Unmet Needs
    • 7.2.1. Curative Therapy for Severe UC Patients
    • 7.2.2. Diagnostic Markers for Disease Severity
    • 7.2.3. Personalized Therapy
    • 7.2.4. A Replacement for Steroids
    • 7.2.5. Novel Oral Drug Formulations
    • 7.2.6. Preventative Medicine for Lowering the Associated Colorectal Cancer Risk
    • 7.2.7. Improved Management of Infectious Adverse Events
  • 7.3. Unmet Needs Gap Analysis
  • 7.4. Disease Severity and Colorectal Cancer Biomarker-Based Prognostic Tools
  • 7.5. Predictors of Medically-Refractory Disease

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Country
  • 8.3. Clinical Trials by Phase and Trial Status
  • 8.4. Promising Drugs in Clinical Development
    • 8.4.1. Etrolizumab
    • 8.4.2. Xeljanz (tofacitinib)
    • 8.4.3. Kappaproct (DIMS 0150)

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Johnson & Johnson
    • 9.3.2. AbbVie
    • 9.3.3. Takeda Pharmaceuticals
    • 9.3.4. Roche
    • 9.3.5. Warner Chilcott
    • 9.3.6. Salix Pharmaceuticals/Santarus
    • 9.3.7. Shire Pharmaceuticals
    • 9.3.8. Ferring Pharmaceuticals
    • 9.3.9. Pfizer
    • 9.3.10. InDeX Pharmaceuticals

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. United Kingdom
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers
  • 10.9. Canada
    • 10.9.1. Forecast
    • 10.9.2. Key Events
    • 10.9.3. Drivers and Barriers
  • 10.10. China
    • 10.10.1. Forecast
    • 10.10.2. Key Events
    • 10.10.3. Drivers and Barriers
  • 10.11. India
    • 10.11.1. Forecast
    • 10.11.2. Key Events
    • 10.11.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed UC Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Physicians and Specialists Included in This Study
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Author
    • 11.7.2. Epidemiologist
    • 11.7.3. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Genetic Factors That Confer a Predisposition to UC
  • Table 2: Typical Symptoms of UC
  • Table 3: Strongest Putative Risk Factors for UC
  • Table 4: Prevalence of UC in the US
  • Table 5: Incidence of UC in the 5EU
  • Table 6: Prevalence of UC in the 5EU
  • Table 7: 10MM, Sources of UC Incidence Data Used in the Epidemiological Forecast
  • Table 8: 10MM, Sources of UC Prevalence Data Used in the Epidemiological Forecast
  • Table 9: 10MM, Incident Cases of UC, Ages ≥10 Years, Both Sexes, N, Select Years, 2012-2022
  • Table 10: 10MM, Incident Cases of UC, By Age, Both Sexes, N (Row %), 2012
  • Table 11: 10MM, Incident Cases of UC, By Sex, Ages ≥10 Years, N (Row %), 2012
  • Table 12: 10MM, Prevalent Cases of UC, Ages ≥10 Years, Both Sexes, N, Select Years, 2012-2022
  • Table 13: 10MM, Prevalent Cases of UC, By Age, Both Sexes, N (Row %), 2012
  • Table 14: 10MM, Prevalent Cases of UC, By Sex, Ages ≥10 Years, N (Row %), 2012
  • Table 15: Truelove and Witts UC Severity Index
  • Table 16: UCDAI
  • Table 17: Treatment Guidelines for UC Used in the 10MM
  • Table 18: Most Commonly Prescribed Drugs for UC by Class in the 10MM, 2013
  • Table 19: UC Management Country Profile - US
  • Table 20: UC Management Country Profile - France
  • Table 21: UC Management Country Profile - Germany
  • Table 22: UC Management Country Profile - Italy
  • Table 23: UC Management Country Profile - Spain
  • Table 24: UC Management Country Profile - UK
  • Table 25: UC Management Country Profile - Japan
  • Table 26: Country Profile - Canada
  • Table 27: UC Management Country Profile - China
  • Table 28: UC Management Country Profile - India
  • Table 29: Leading Treatments for UC, 2014
  • Table 30: Product Profile - Remicade
  • Table 31: Remicade SWOT Analysis, 2014
  • Table 32: Global Sales Forecasts ($m) for Remicade, 2012-2022
  • Table 33: Product Profile - Humira
  • Table 34: Humira Efficacy in the ULTRA 2 Trial
  • Table 35: Product Efficacy Comparison - Humira vs. Remicade
  • Table 36: Humira SWOT Analysis, 2014
  • Table 37: Global Sales Forecasts ($m) for Humira, 2012-2022
  • Table 38: Product Profile - Simponi
  • Table 39: Simponi SWOT Analysis, 2014
  • Table 40: Global Sales Forecasts ($m) for Simponi, 2012-2022
  • Table 41: Product Profile - Entyvio
  • Table 42: Results of the GEMINI I Trial, Efficacy of Vedolizumab in the Induction of Remission in UC
  • Table 43: Results of the GEMINI I Trial, Efficacy of Vedolizumab in the Maintenance of Remission in UC
  • Table 44: Most Common Adverse Events with Vedolizumab in the GEMINI I Study
  • Table 45: Entyvio SWOT Analysis, 2014
  • Table 46: Global Sales Forecasts ($m) for Entyvio, 2012-2022
  • Table 47: Product Profile - Apriso
  • Table 48: Apriso SWOT Analysis, 2014
  • Table 49: Global Sales Forecasts ($m) for Apriso, 2012-2022
  • Table 50: Product Profile - Asacol HD
  • Table 51: Asacol HD SWOT Analysis, 2014
  • Table 52: Global Sales Forecasts ($m) for Asacol HD, 2012-2022
  • Table 53: Product Profile - Lialda
  • Table 54: Lialda SWOT Analysis, 2014
  • Table 55: Global Sales Forecasts ($m) for Lialda, 2012-2022
  • Table 56: Product Profile - Pentasa
  • Table 57: Pentasa SWOT Analysis, 2014
  • Table 58: Global Sales Forecasts ($m) for Pentasa, 2012-2022
  • Table 59: Product Profile - Colazal
  • Table 60: Colazal SWOT Analysis, 2014
  • Table 61: Global Sales Forecasts ($m) for Colazal, 2012-2022
  • Table 62: Product Profile - Giazo
  • Table 63: Giazo SWOT Analysis, 2014
  • Table 64: Global Sales Forecasts ($m) for Giazo, 2012-2022
  • Table 65: Product Profile - sfRowasa
  • Table 66: sfRowasa SWOT Analysis, 2014
  • Table 67: Global Sales Forecasts ($m) for sfRowasa, 2012-2022
  • Table 68: Product Profile - Uceris
  • Table 69: Uceris SWOT Analysis, 2014
  • Table 70: Global Sales Forecasts ($m) for Uceris, 2012-2022
  • Table 71: Summary of Other Immunomodulators for UC, 2013
  • Table 72: Biosimilars Pipeline, 2014
  • Table 73: Global Sales Forecasts ($m) for Infliximab Biosimilars, 2012-2022
  • Table 74: Global Sales Forecasts ($m) for Adalimumab Biosimilars, 2012-2022
  • Table 75: Global Sales Forecasts ($m) for Golimumab Biosimilars, 2012-2022
  • Table 76: Overall Unmet Needs - Current Level of Attainment
  • Table 77: Corticosteroid Long-Term Side Effects
  • Table 78: Clinical Unmet Needs in UC - Gap Analysis, 2013
  • Table 79: Prognostic Markers in UC
  • Table 80: UC - Clinical Trials by Phase and Status, 2014
  • Table 81: UC - Pre-Registration and Phase III Pipeline, 2014
  • Table 82: Comparison of Therapeutic Classes in Development for UC, 2014
  • Table 83: Product Profile - Etrolizumab
  • Table 84: Results of Phase IIa Trial of Etrolizumab in the Induction of Remission in UC
  • Table 85: Most Common Adverse Events in the Phase IIa Trial of etrolizumab
  • Table 86: Etrolizumab SWOT Analysis, 2014
  • Table 87: Global Sales Forecasts ($m) for Etrolizumab, 2012-2022
  • Table 88: Product Profile - Xeljanz
  • Table 89: Results of Phase IIa Trial of Xeljanz in the Induction of Remission in UC
  • Table 90: Most Common Adverse Events in the Phase IIa Trial of Xeljanz
  • Table 91: Xeljanz SWOT Analysis, 2014
  • Table 92: Global Sales Forecasts ($m) for Xeljanz, 2012-2022
  • Table 93: Product Profile - Kappaproct
  • Table 94: Results of Phase IIb Trial of Kappaproct in the Induction of Remission in UC
  • Table 95: Kappaproct SWOT Analysis, 2014
  • Table 96: Global Sales Forecasts ($m) for Kappaproct, 2012-2022
  • Table 97: Key Companies in the UC Market, 2012-2022
  • Table 98: J&J's UC Portfolio Assessment, 2014
  • Table 99: J&J's SWOT Analysis in UC, 2014
  • Table 100: AbbVie's UC Portfolio Assessment, 2014
  • Table 101: AbbVie's UC SWOT Analysis, 2014
  • Table 102: Takeda Pharmaceuticals' UC Portfolio Assessment, 2014
  • Table 103: Takeda's UC SWOT Analysis, 2014
  • Table 104: Roche's UC Portfolio Assessment, 2014
  • Table 105: Roche's UC SWOT Analysis, 2014
  • Table 106: Warner Chilcott's UC Portfolio Assessment, 2014
  • Table 107: Warner Chilcott's UC SWOT Analysis, 2014
  • Table 108: Salix Pharmaceuticals/Santarus UC Portfolio Assessment, 2013
  • Table 109: Salix Pharmaceuticals/Santarus UC SWOT Analysis, 2014
  • Table 110: Shire Pharmaceuticals' UC Portfolio Assessment, 2014
  • Table 111: Shire Pharmaceuticals' UC SWOT Analysis, 2014
  • Table 112: Ferring Pharmaceuticals' UC Portfolio Assessment, 2013
  • Table 113: Ferring Pharmaceutical's UC SWOT Analysis, 2014
  • Table 114: Pfizer's UC Portfolio Assessment, 2014
  • Table 115: Pfizer's UC SWOT Analysis, 2014
  • Table 116: InDeX Pharmaceuticals' UC Portfolio Assessment, 2013
  • Table 117: InDeX Pharmaceuticals' UC SWOT Analysis, 2014
  • Table 118: Global Sales Forecasts ($m) for UC, 2012-2022
  • Table 119: Global UC Market - Drivers and Barriers, 2012-2022
  • Table 120: Sales Forecasts ($m) for UC in the US, 2012-2022
  • Table 121: Key Events Impacting Sales for UC in the US, 2012-2022
  • Table 122: UC Market in the US - Drivers and Barriers, 2012-2022
  • Table 123: Sales Forecasts ($m) for UC in France, 2012-2022
  • Table 124: Key Events Impacting Sales for UC in France, 2012-2022
  • Table 125: UC Market in France - Drivers and Barriers, 2012-2022
  • Table 126: Sales Forecasts ($m) for UC in Germany, 2012-2022
  • Table 127: Key Events Impacting Sales for UC in Germany, 2012-2022
  • Table 128: UC Market in Germany - Drivers and Barriers, 2012-2022
  • Table 129: Sales Forecasts ($) for UC in Italy, 2012-2022
  • Table 130: Key Events Impacting Sales for UC in Italy, 2012-2022
  • Table 131: UC Market in Italy - Drivers and Barriers, 2012-2022
  • Table 132: Sales Forecasts ($m) for UC in Spain, 2012-2022
  • Table 133: Key Events Impacting Sales for UC in Spain, 2012-2022
  • Table 134: UC Market in Spain - Drivers and Barriers, 2012-2022
  • Table 135: Sales Forecasts ($m) for UC in the UK, 2012-2022
  • Table 136: Key Events Impacting Sales for UC in the UK, 2012-2022
  • Table 137: UC Market in the UK - Drivers and Barriers, 2012-2022
  • Table 138: Sales Forecasts ($) for UC in Japan, 2012-2022
  • Table 139: Key Events Impacting Sales for UC in Japan, 2012-2022
  • Table 140: UC Market in Japan - Drivers and Barriers, 2012-2022
  • Table 141: Sales Forecasts ($m) for UC in Canada, 2012-2022
  • Table 142: Key Events Impacting Sales for UC in Canada, 2012-2022
  • Table 143: UC Market in Canada - Drivers and Barriers, 2012-2022
  • Table 144: Sales Forecasts ($) for UC in China, 2012-2022
  • Table 145: Key Events Impacting Sales for UC in China, 2012-2022
  • Table 146: UC Market in China - Drivers and Barriers, 2012-2022
  • Table 147: Sales Forecasts ($) for UC in India, 2012-2022
  • Table 148: Key Events Impacting Sales for UC in India, 2012-2022
  • Table 149: UC Market in India - Drivers and Barriers, 2012-2022
  • Table 150: Key launches for Ulcerative Colitis , 2012-2022
  • Table 151: Key Patent Expiries
  • Table 152: Annual Cost of Therapy for 5-ASAs ($)
  • Table 153: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Cellular Mechanisms Involved in the Pathogenesis of UC
  • Figure 2: Olmsted Country, Minnesota, US, Age- and Sex-Adjusted Incidence of UC, Cases per 100,000 Population, 1940-2000
  • Figure 3: Canada, Incidence and Prevalence of UC, Cases per 100,000 Population, 1990-2001
  • Figure 4: Hong Kong, China, Crude Incidence and Prevalence of UC, Cases per 100,000 Population, 1997-2006
  • Figure 5: 10MM, Incident Cases of UC, Ages ≥ 10 Years, Both Sexes, N, 2012-2022
  • Figure 6: 10MM, Incident Cases of UC, By Age, Both Sexes, N, 2012
  • Figure 7: 10MM, Incident Cases of UC, By Sex, Ages ≥10 Years, N, 2012
  • Figure 8: 10MM, Age-Standardized Incidence of UC, Ages ≥10 Years, Both Sexes, Cases per 100,000 Population, 2012
  • Figure 9: 10MM, Prevalent Cases of UC, Ages ≥10 Years, Both Sexes, N, 2012-2022
  • Figure 10: 10MM, Prevalent Cases of UC, By Sex, Ages ≥ 10 Years, N, 2012
  • Figure 11: 10MM, Prevalent Cases of UC, By Sex, Ages ≥10 Years, N, 2012
  • Figure 12: 10MM, Age-Standardized Prevalence of UC, Ages ≥10 Years, Both Sexes, %, 2012
  • Figure 13: UC Disease Management Flowchart
  • Figure 14: UC Therapeutics - Clinical Trials by Country, 2014
  • Figure 15: Competitive Assessment of Late-Stage Pipeline Agents UC, 2012-2022
  • Figure 16: Company Portfolio Gap Analysis in UC, 2012-2022
  • Figure 17: Global Sales ($m) for UC by Region, 2012-2022
  • Figure 18: Sales for UC in the US by Drug Class, 2012-2022
  • Figure 19: Sales for UC in France by Drug Class, 2012-2022
  • Figure 20: Sales for UC in Germany by Drug Class, 2012-2022
  • Figure 21: Sales for UC in Italy by Drug Class, 2012-2022
  • Figure 22: Sales for UC in Spain by Drug Class, 2012-2022
  • Figure 23: Sales for UC in the UK by Drug Class, 2012-2022
  • Figure 24: Sales for UC in Japan by Drug Class, 2012-2022
  • Figure 25: Sales for UC in Canada by Drug Class, 2012-2022
  • Figure 26: Sales for UC in China by Drug Class, 2012-2022
  • Figure 27: Sales for UC in India by Drug Class, 2012-2022
Back to Top